Health

Business Wire Australia and New Zealand

People with idiopathic pulmonary fibrosis (IPF) reveal high burden of disease in new survey

24-Jul-2017 5:24 PM
• 61% of IPF patients are worried or extremely worried about experiencing an acute IPF exacerbation1 • Survey underlines the importance of appropriate support and coping mechanisms for patients living with IPF1 • Healthcare teams emphasise th

Business Wire Australia and New Zealand

Janssen Receives Positive CHMP Opinion for SYMTUZA™ The First Darunavir-Based Single-Tablet Regimen for the Treatment of HIV

24-Jul-2017 8:43 AM
  Proven efficacy and durability of darunavir combined with the improved renal laboratory and bone mineral density profile of emtricitabine/tenofovir alafenamide as compared to emtricitabine/tenofovir disoproxil fumarate into one single tab

Business Wire Australia and New Zealand

Masimo Announces CE Marking of Noninvasive RPVi™, a rainbow® Multi-Wavelength Index of Pleth Variability

20-Jul-2017 4:15 PM
Masimo Radical-7® Pulse CO-Oximeter® with RPVi™ (Photo: Business Wire) NEUCHATEL, Switzerland--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) announced today the CE marking of RPVi™, a noninvasive and continuous measurement of the dynamic cha

Business Wire Australia and New Zealand

Minomic Launches US Prospective Study of MiCheck® Prostate Cancer Test

18-Jul-2017 9:08 AM
Novel prostate cancer screening technology targeting commercialization in 2017 Verification of test accuracy and reliability for CLIA lab access SYDNEY--(BUSINESS WIRE)--Minomic International Ltd, an Australian immuno-oncology com

Business Wire Australia and New Zealand

PSMF Convenes the International Patient Safety Community for its 2017 Midyear Planning Meeting at Inova Center for Personalized Health

14-Jul-2017 4:31 PM
IRVINE, Calif.--(BUSINESS WIRE)--The Patient Safety Movement Foundation (PSMF) brought together over 100 medical care providers, hospital administrators, and patient safety experts and advocates to discuss ongoing challenges and refine

Business Wire Australia and New Zealand

Final Phase III Study Results Confirm Benefit of Praxbind® as Reversal Agent for Pradaxa® Patients in Emergency Situations

11-Jul-2017 6:52 PM
Complete data set from 503 patients show that Praxbind® (idarucizumab) led to immediate, complete and sustained reversal of the anticoagulant effect of Pradaxa® (dabigatran etexilate) in emergency settings1 Final results from RE-VE

Business Wire Australia and New Zealand

ABEC Sets a New Benchmark in Single Use Bioreactor Capacity

11-Jul-2017 7:45 AM
ABEC increases the maximum capacity of its Custom Single Run (CSR®) Bioreactors to 4,000 liters, doubling the industry standard BETHLEHEM, Pa.--(BUSINESS WIRE)--ABEC, a leading global provider of integrated solutions and services for

Business Wire Australia and New Zealand

The Broad Institute of MIT and Harvard Among Those Participating in MPEG LA’s CRISPR-Cas9 Joint Licensing Facilitation

11-Jul-2017 7:28 AM
Patent submissions continue to be accepted DENVER--(BUSINESS WIRE)--World licensing leader MPEG LA, LLC is pleased to announce that key CRISPR patent holders have submitted patents in response to MPEG LA’s call to participat

Business Wire Australia and New Zealand

ISTH 2017, Berlin: Octapharma presents exciting Nuwiq® data in previously untreated patients and demonstrates real-life value of personalised prophylaxis for Haemophilia A

10-Jul-2017 4:51 PM
LACHEN, Switzerland--(BUSINESS WIRE)--Octapharma is playing a prominent role this week at the International Society on Thrombosis and Haemostasis (ISTH) Congress in Berlin, Germany. As a platinum sponsor of the congress, Octapharma’s active i

Business Wire Australia and New Zealand

Masimo Announces CE Marking of rainbow® Super Sensor

10-Jul-2017 4:39 PM
Masimo Super Sensor is the First Ever to Measure Arterial Oxygen Saturation (SpO2), Hemoglobin (SpHb®), Carboxyhemoglobin (SpCO®), Methemoglobin (SpMet®), Pleth Variability Index (PVi®), Index of Perfusion (Pi), and Pulse Rate (PR), All

Business Wire Australia and New Zealand

Promega Intends to Seek FDA Approval for Microsatellite Instability Assay to Assist in Strategic Cancer Decisions

07-Jul-2017 10:21 AM
Promega Corporation intends to seek FDA approval and CE-IVD marking for a commercially available Microsatellite Instability (MSI) assay to assist oncologists and pathologists in determining colorectal cancer decisions. The current P

Business Wire Australia and New Zealand

Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers

06-Jul-2017 12:13 PM
  Celgene accelerates its immuno-oncology strategy in solid tumors with acquisition of worldwide rights, rest of world outside Asia, to BeiGene’s PD-1 inhibitor BGB-A317; Pivotal BGB-A317 solid tumor studies planned for 2018 Co

Business Wire Australia and New Zealand

Zebra Medical Vision: First Artificial Intelligence Deployment at Scale to Improve Medical Imaging Diagnosis in 20 Developing Countries

05-Jul-2017 5:00 PM
The partnership will integrate Zebra-med’s analytics engine with Telerad Tech’s RADSpa, a cloud based integrated PACS/RIS platform, and will be signed along with other cross-country collaborations during the visit of India’s Prime Minister

Royal Flying Doctor Service

Cultural safety needed to prevent Aboriginal people receiving poorer health treatment

05-Jul-2017 6:15 AM
An article authored by Prof Dennis McDermott (Flinders University), Prof Tom Calma (Reconciliation Australia) and Martin Laverty (Royal Flying Doctor service of Australia) has just been published in the Medical Journal of Australia.

Business Wire Australia and New Zealand

Ferring Appoints Lars Peter Brunse to Executive Board

03-Jul-2017 6:05 PM
SAINT-PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals announced today that Lars Peter Brunse has been appointed Executive Vice President and Chief Production Officer, and made a member of the Ferring Executive Board, effective imm

Business Wire Australia and New Zealand

Minomic Clinical Study Progresses For MiltuximabTM In Prostate, Bladder, and Pancreatic Cancer

29-Jun-2017 11:54 AM
Drug Safety Monitoring Committee Approval to Proceed to Final Six Patients of Twelve First-in-human trial on safety and tolerability passes key stage-gate   SYDNEY--(BUSINESS WIRE)--Australian immuno-oncology company Minomic Internation

Business Wire Australia and New Zealand

Groundbreaking Multi-Center Clinical Trial Confirms Low-Dose Aspirin Therapy Reduces Rate of Pre-Term Preeclampsia

29-Jun-2017 9:17 AM
  Project “ASPRE” Study Utilized PerkinElmer’s DELFIA Xpress PlGF 1-2-3 Assay to Identify Women who Would Benefit from Low-Dose Aspirin LJUBLJANA, Slovenia--(BUSINESS WIRE)--PerkinElmer, Inc., a global leader committed to innov

Business Wire Australia and New Zealand

Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma

27-Jun-2017 8:42 AM
CAMBRIDGE, Mass., OSAKA, Japan & BOTHELL, Wash.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that the Phase 3 ECHELON-1 clinical trial met its primary endpo

Business Wire Australia and New Zealand

Takeda Presents Data from Phase 1/2 Studies for NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma Patients and in the Maintenance Setting

23-Jun-2017 5:36 PM
– Early studies of weekly and twice-weekly ixazomib plus lenalidomide and dexamethasone demonstrate deep responses after induction, with deepening responses seen after single-agent ixazomib maintenance – – Data to be presented during two or

Business Wire Australia and New Zealand

Augmenix Announces First Prostate Cancer Patient Treated with SpaceOAR® Hydrogel in New Zealand

22-Jun-2017 10:31 AM
Kathleen Kilgour Centre is the first cancer center in New Zealand to offer this innovative product to their community SpaceOAR hydrogel separates the prostate and rectum during radiation treatment (Photo: Business Wire) TAUR